Rock Springs Capital Management LP Sells 228,303 Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Rock Springs Capital Management LP cut its holdings in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 32.6% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 471,086 shares of the biopharmaceutical company's stock after selling 228,303 shares during the quarter. Rock Springs Capital Management LP owned approximately 0.83% of Agios Pharmaceuticals worth $15,480,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in AGIO. Tower Research Capital LLC TRC increased its holdings in Agios Pharmaceuticals by 236.6% during the fourth quarter. Tower Research Capital LLC TRC now owns 10,286 shares of the biopharmaceutical company's stock worth $338,000 after buying an additional 7,230 shares during the last quarter. MetLife Investment Management LLC lifted its stake in Agios Pharmaceuticals by 5.9% in the fourth quarter. MetLife Investment Management LLC now owns 34,579 shares of the biopharmaceutical company's stock valued at $1,136,000 after purchasing an additional 1,916 shares during the last quarter. Guggenheim Capital LLC bought a new position in Agios Pharmaceuticals during the fourth quarter valued at $450,000. XTX Topco Ltd lifted its position in shares of Agios Pharmaceuticals by 11.3% during the 4th quarter. XTX Topco Ltd now owns 9,272 shares of the biopharmaceutical company's stock valued at $305,000 after buying an additional 943 shares during the last quarter. Finally, Summit Investment Advisors Inc. lifted its position in shares of Agios Pharmaceuticals by 7.1% during the 4th quarter. Summit Investment Advisors Inc. now owns 5,913 shares of the biopharmaceutical company's stock valued at $194,000 after buying an additional 394 shares during the last quarter.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on AGIO. HC Wainwright assumed coverage on Agios Pharmaceuticals in a research note on Monday, February 24th. They issued a "buy" rating and a $58.00 price objective on the stock. StockNews.com cut shares of Agios Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Friday, February 14th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Hold" and an average target price of $56.57.

Insiders Place Their Bets

In other Agios Pharmaceuticals news, Director Jacqualyn A. Fouse sold 7,497 shares of Agios Pharmaceuticals stock in a transaction dated Thursday, April 10th. The stock was sold at an average price of $25.90, for a total transaction of $194,172.30. Following the completion of the sale, the director now owns 149,220 shares of the company's stock, valued at $3,864,798. The trade was a 4.78 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Corporate insiders own 4.93% of the company's stock.

Agios Pharmaceuticals Price Performance

NASDAQ:AGIO traded up $0.89 during trading hours on Thursday, hitting $29.26. The stock had a trading volume of 378,770 shares, compared to its average volume of 705,406. The company has a 50 day simple moving average of $30.38 and a two-hundred day simple moving average of $38.33. The firm has a market capitalization of $1.68 billion, a price-to-earnings ratio of 2.58 and a beta of 0.83. Agios Pharmaceuticals, Inc. has a one year low of $23.42 and a one year high of $62.58.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last posted its earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.74) EPS for the quarter, missing the consensus estimate of ($1.69) by ($0.05). Agios Pharmaceuticals had a negative return on equity of 2.51% and a net margin of 1,845.92%. Equities research analysts anticipate that Agios Pharmaceuticals, Inc. will post -6.85 earnings per share for the current year.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.